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Abstract 
Background: The re-expression of pluripotent markers (Oct-4 and Nanog) and the 
reactivation of stem cell related pathways in oral carcinoma have been well researched. 
However, the relationship between the stem cell signaling molecule β-catenin and 
pluripotent markers Oct-4 and Nanog in oral cancer, is yet to be studied in detail.  
Therefore, we have investigated the correlation between Oct-4, Nanog and β-catenin in 
oral squamous cell carcinoma which in turn could provide valuable insight into its 
prognostic significance. 
Methods: The Immunohistochemical analysis was performed for 60 cases of oral cancer 
to study the expression pattern of Oct-4, Nanog and β-catenin. Whereas, 
Immunofluorescence analysis was used to investigate the co-localization of β-catenin 
with Oct-4 and Nanog in oral carcinoma tissues and H314 cell line. Finally, Co-
immunoprecipitation analysis was used to study the possible interaction between β-
catenin and Oct-4 in oral carcinoma cells.  
Results: β-catenin, Oct-4 and Nanog showed significant correlation with lymph node 
metastasis, stage, grade and prognosis in oral squamous cell carcinoma. Interestingly, a 
significant positive correlation was found between the expression of Oct-4, Nanog and β-
catenin. Moreover, the interaction between β-catenin and Oct-4 was observed in oral 
cancer.  
Conclusions: The positive correlation between Oct-4, Nanog and β-catenin suggests their 
coordinated role in maintaining proliferation in oral carcinoma cells. The interaction 
between β-catenin and Oct-4 may be a crucial event in oral carcinogenesis. On the other 
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hand, β-catenin, Oct-4 and Nanog could be used as independent prognostic markers of 
oral squamous cell carcinoma. 
Keywords: β-catenin; Cancer stem cells; Oct-4; Oral squamous cell carcinoma; Nanog. 
Introduction 
The transformation from the precancerous to cancerous stage in oral cancer is 
accompanied with genomic alterations [1]. Apart from the somatic mutation theory of 
carcinogenesis, the cancer stem cell hypothesis has become the basis for many novel 
treatment strategies for cancer. The cancer stem cell hypothesis states that a 
subpopulation of cells in cancerous tissues with tumor inducing capacity as well as stem 
cell-like characteristics is responsible for carcinogenesis.  These cells are termed as 
cancer stem cells [2]. However, studies on the molecular mechanisms related to cancer 
stem cells remains obscure. Recently, the expression of stem cell markers Oct-4, Nanog, 
CD133 and Musashi-1 has been demonstrated in oral squamous cell carcinoma [3, 4]. 
Additionally, the reactivation of Wnt / β-catenin pathway was observed in oral cancer [5]. 
Interestingly, several studies show association among β-catenin, Oct-4 and Nanog in 
embryonic stem cells [6, 7]. Based on this background, we have investigated the 
expression pattern and relationship between Oct-4, Nanog and β-catenin in oral squamous 
cell carcinoma, which will provide new insights into the coordinated role of β-catenin, 
Oct-4 and Nanog in oral cancer. We also analyzed their correlation with 
clinicopathological factors and prognosis.  
 
In addition to its role in cell-cell adhesion, β-catenin is also a component of the Wnt 
signaling cascade. Wnt/β-catenin is one of the major pathways which regulates 
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proliferation and differentiation of stem cells [8]. In the normal state, β-catenin is mainly 
present as Axin-APC- β-catenin complex, phosphorylated by GSK3β. Upon activation, 
the β-catenin gets separated from the complex, enters into the nucleus and together with 
Lef/Tcf family of DNA binding proteins, it activates target genes including c-Myc and 
Cyclin D1. In addition to its role in maintaining stemness of embryonic stem cells, β-
catenin was found to have a significant role in several tumors including oral squamous 
cell carcinoma, particularly the malignant transformation of oral dysplasia is associated 
with the intracellular expression of β-catenin. [5, 9]. The expression of β-catenin was 
associated with invasion and metastasis of oral carcinoma cells thereby leading to poor 
prognosis [5]. Recently, it was found that β-catenin maintains the self-renewal of 
embryonic stem cells by interacting with Oct-4 and subsequently upregulating Nanog [7]. 
Since, a relationship between β-catenin and Oct-4 was found in cancer cells and 
embryonic stem cells, it was evident that β-catenin might maintain the characteristics of 
cancer stem cells along with Oct-4 [10, 7]. Previously, we have found a positive 
relationship and interaction between β-catenin and keratinocyte stem/progenitor cell 
marker ∆Np63 in maintaining proliferation of oral carcinoma cells [5]. Therefore, to 
extend our knowledge on the relationship between β-catenin and other stem cell markers, 
we have investigated the correlation between Oct-4, Nanog and β-catenin in oral 
carcinoma.  
 
Oct-4 is a nuclear protein that belongs to a family of transcription factors containing the 
POU DNA binding domain [11].  Oct-4 plays a key role in mammalian development and 
helps in understanding the early events in somatic differentiation of the developing 
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embryo. It was found that Oct-4 regulates the self-renewal and differentiation in 
embryonic stem cells [11, 12], while its expression in adult stem cells with an 
undifferentiated phenotype helps in the maintenance of pluripotency of the population.  
Oct-4 also helps in identifying adult stem cells which might act as candidates for the 
initiation of carcinogenesis [13, 14]. Recently, Oct-4 expression was observed in cell 
lines derived from tissues of the breast, colon, lung and oral cancers. Interestingly, 
continuous activation of Oct-4 in epithelial cells causes dysplasia which in turn leads to 
carcinoma [15, 16, 3].  Studies have clearly revealed that the expression of Oct-4 was 
synchronized with that of Nanog in cancer [17].  
 
Nanog is a homeodomain transcription factor that helps in maintaining the self-renewal 
capacity in embryonic stem cells. It determines the cell fate of inner cell mass (ICM) 
during embryonic development. In embryonic stem cells, Nanog is found to act parallel 
with Oct-4 [18]. Though Nanog was not fund in adult tissues, it was observed in several 
tumors including seminomas, breast cancer, cervical cancer and oral cancer [19, 20, 3]. 
The co-expression of Nanog with Oct-4 was found in pancreatic carcinogenesis while in 
lung adenocarcinoma, they were found to induce cancer stem cell-like properties [21, 17]. 
However, the expression of Nanog was found even in Oct-4 deficient embryo [18]. The 
overexpression of Nanog promotes recurrence in cisplatin - treated oral squamous cell 
carcinoma patients and was found to induce the transformation of NIH3T3 cells [22, 23]. 
Moreover, Nanog was found to regulate the self-renewal potential in hepatocellular 
cancer stem cells through the Insulin-like growth factor (IGF) pathway [24]. As 
mentioned earlier, β-catenin upregulates Nanog expression in embryonic stem cells by 
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binding with the Lef/Tcf element in the enhancer region of the human NANOG gene 
[25].  
 
In order to support the role of β-catenin in maintaining proliferation of oral cancer cells, 
the expression pattern of the keratinocyte differentiation marker Involucrin was also 
investigated in oral cancer. Involucrin is a cell envelope protein identified as a marker for 
terminal differentiation of keratinocytes.  Involucrin expression in poorly differentiated 
tumors is much less than in cells of well differentiated tumors.  Involucrin expression is 
also dependent on the level of hypoxia in the tumor tissues [26]. During the in vitro 
differentiation of human embryonic stem cells to keratinocytes, the expression of 
Involucrin was found only during the initiation of keratinocyte differentiation [27].   
 
Eventhough several studies show the involvement of stem cell markers and signaling 
molecules in oral squamous cell carcinoma, the association between Oct-4, Nanog and β-
catenin has not yet been studied.  Additionally, the correlation between Oct-4, Nanog and 
clinicopathological factors has not been extensively studied in oral cancer. Hence, 
studying the expression pattern of these proteins will uncover novel facets of their role in 
oral squamous cell carcinoma. Therefore, we have investigated the expression pattern and 
association between Oct-4, Nanog and β-catenin in oral carcinoma. We have also 
analyzed the prognostic significance of these proteins in oral cancer which will in turn 
play a pivotal role while determining therapeutic strategies. 
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Materials & Methods: 
Tissues & Cell line 
The samples used in this study were obtained from 60 patients, aged between 45 and 70, 
with a mean age of 59.3.  The tissue samples were obtained with proper consent from the 
patients referred to the Department of Surgical Oncology, Government Royapettah 
Hospital, Chennai. Six normal samples were obtained from the patients undergoing 
orthodontic surgery. The range of follow-up was 14 to 48 months with a mean follow-up 
period of 31.9. Histopathological parameters were assessed according to the criteria 
illustrated by Pindborg et al [28]. 10% buffered formalin was used for fixing the tissues 
and they were processed for paraffin embedding. 4 µm sections were mounted on coated 
glass slides. Clearance for the study was obtained from the Hospital Medical Board with 
permission from the Directorate of Medical Education, Government of Tamil Nadu, 
India.  
The cell-bearing slides of H314 cell line (derived from a poorly differentiated tumour of 
the floor of the mouth) [29] and cell-bearing coverslips of CAL27 cell line (Human 
tongue squamous cell carcinoma) [30] were obtained as gift from Dr. Angela Hague and 
Dr. Karl Kingsley respectively. 
Immunohistochemistry 
Sections were deparaffinized in xylene, rehydrated through graded alcohols and the 
antigen retrieval was done by heating the slides in 0.1M sodium citrate buffer (pH 6.0) in 
a microwave oven. After cooling, the endogenous peroxidase activity was blocked by 
placing the slides in 3 % hydrogen peroxide for 10 minutes.  The non-specific binding 
sites were blocked with 0.3% Bovine Serum Albumin (BSA) for 30 minutes at room 
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temperature. The sections were then incubated (overnight at 4
o
C) with mouse monoclonal 
anti-Oct-4 (Santa Cruz Biotech, USA; sc-5279), rabbit polyclonal anti-β-catenin (Santa 
Cruz Biotech., USA; sc-7199) and goat polyclonal anti-Nanog (Santa Cruz Biotech., 
USA; sc-30331) in a dilution of 1:200 for all the above mentioned antibodies. 
Additionally, the cases showing intracellular expression of β-catenin were also incubated 
with mouse monoclonal anti-Involucrin antibody (a kind gift from Dr.Fiona Watt, UK; 
SY5; 1:100). The slides were immunostained using the respective horseradish peroxidase 
conjugated secondary antibodies (Invitrogen, USA). The chromogen 3, 3’ 
diaminobenzidine was then used as a substrate for localizing the antibody binding. After 
Counter-staining with haematoxylin, the sections were mounted and viewed under 
microscope. Negative controls without primary antibody were included for each staining. 
The deparaffinization step was omitted in the case of CAL27 cells. The immunostained 
sections were scored according to the percentage of stained cells in more than three 
random areas of cancer tissue as examined in 200x magnification.   Two independent 
observers without prior knowledge on the patient’s clinicopathological data assessed the 
immunostained slides. The staining was assessed as 0 (negative), no staining or staining 
in less than 5% of cells; 1
+
 (mild), staining in 5-15% of carcinoma cells; 2
+ 
(moderate), 
staining in 16-25% of carcinoma cells; 3
+
 (intense), staining in >25% of carcinoma cells.  
The staining was also graded as Negative (includes categories 0 and 1
+
) and Positive 
(includes categories 2
+ 
and
 
3
+
). Additionally, the localization of β-catenin was considered 
as 0, negative; M, membranous and I, intracellular, to study the correlation of β-catenin 
localization with the expression of Oct-4 and Nanog.  In case of disagreement, the slides 
were re-evaluated by the two observers and a consensus was reached after discussion.    
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Immunofluorescence 
The Immunofluorescence analysis was done in carcinoma tissues and in H314 cell line. 
The sections were deparaffinized in xylene, rehydrated and fixed for 5 minutes. The cells 
were then washed with Phosphate Buffer Saline (PBS) and permeabilized with 0.1% 
Triton X-100. The cells were then blocked with 1% BSA for 30 minutes and incubated (1 
hour) with a combination of anti-β-catenin / anti-Oct 4 and anti-β-catenin / anti-Nanog 
antibodies. In addition, the H314 cells were also incubated with a combination of anti-β-
catenin / anti-Involucrin antibodies. After washing with PBS, the slides were incubated 
for 2 hours with respective FITC conjugated secondary antibodies for Oct-4, Nanog and 
Involucrin and Alexa Fluor 594 (red) conjugated secondary antibody for β-catenin. After 
incubation, the slides were washed with PBS, mounted and examined under confocal 
fluorescence microscope (Leica TCS SP2, Leica Microsystems, Germany). Fluoroshield 
Mounting medium with DAPI (Sigma, USA) was used for DAPI staining and the staining 
was done according to the manufacturer’s protocol. 
Western blot and Co-immunoprecipitation 
Western blot and co-immunoprecipitation analysis were done in 16 cases including 
normal (6) and carcinoma (10).  The protein lysates were prepared as described by 
Ratovitski et al [31] and immunoblotted as input control. The protein concentrations were 
measured by Lowry’s method [32].  Samples were separated on 10% SDS-
polyacrylamide gels, transferred to nitrocellulose membrane and the membranes were 
blocked in Tris-buffered saline containing 5% skim milk and 0.05% Tween-20. The 
membranes were then incubated with anti- β-catenin, anti-Oct-4 and anti-Nanog 
antibodies and the western blot was performed using the respective horseradish 
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peroxidase (HRP) conjugated secondary antibodies. The signals were detected using 
Amersham ECL plus kit according to the manufacturer’s protocol.  For co-
immunoprecipitation, the β-catenin immune complex was prepared as described in our 
previous report [5] and the immune complex was then incubated with 20µl of protein-A-
sepharose beads (Sigma) for 30 minutes. The immunocomplex were centrifuged, washed 
in homogenizing buffer and the pellets were resuspended in sample buffer. The 
immunoprecipitates were separated by SDS-PAGE and transferred to nitrocellulose 
membrane. The membrane was then incubated with anti-Oct 4 antibody and the 
Immunoblot analysis was performed as described above. The cell lysates were 
immunoprecipitated with IgG (Santa Cruz Biotech, USA) and used as negative control. 
Statistical analysis 
The relationship between clinicopathological parameters and the expression of proteins 
were analyzed using Chi square test. The correlation between β-catenin, Oct-4 and Nanog 
was statistically evaluated using Spearman’s correlation analysis. The overall and 
disease-free survival curves were constructed by the Kaplan-Meier method and the log-
rank test was used to assess the difference between resulting curves. The duration of 
disease-free survival was between the date of treatment to the date of recurrence or 
metastasis or disease related death. The cases were censored either at the date of death for 
patient who died during the trial or at the date of last examination for patient who lost the 
follow-up. The Univariant and Multivariant survival analyses were performed using Cox 
proportional hazards regression model. The statistical analyses were performed using 
Acastat Statistical software, version 6.1[Acastat Software, USA] and the survival analysis 
was performed using SPSS software (SPSS for windows 14.0, SPSS Inc., Chicago, 
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Illinois). The p<0.05 was considered significant for all the statistical analyses. Due to the 
exploratory nature of the study, we did not adjust for multiple tests. 
Results 
Expression pattern of β-catenin, Oct-4 and Nanog in oral squamous cell carcinoma 
tissues  
β-catenin 
The expression pattern of β-catenin, Oct-4 and Nanog are presented in Table 1.  Out of 60 
cases of oral carcinoma, 10 cases showed negative and 9 cases showed mild staining for 
β-catenin. In addition, 11 and 30 cases showed moderate and intense staining 
respectively. Aberrant localization of β-catenin was observed in oral carcinoma cells 
(Figure 1A (a)). Among the 60 cases of oral squamous cell carcinoma, 30 cases showed 
intracellular expression of β-catenin. The expression of β-catenin did not associate with 
age, gender and location of tumors (P>0.05). However, significant correlation was found 
between stage (x
2
 = 6.163; P<0.01*), lymph node metastasis (x
2
 = 8.155; P<0.004**), 
histological grade (x
2
 = 6.181; P<0.04*) and β-catenin expression (Table 2). Also, intense 
expression of β-catenin was found in CAL27 cells (Figure 2A (a)).  
0ct-4 
 Differential expression pattern of Oct-4 was observed in oral carcinoma tissues. The 
nuclear expression of Oct-4 was considered as ‘positive staining’. The expression of Oct-
4 was predominantly observed in the nucleus but was also found in the cytoplasm of 
some carcinoma cells (Figure 1A (b)). Intense staining of Oct-4 was observed in 18 cases 
of oral carcinoma, whereas, 20 cases showed negative staining for Oct-4. Among the 
remaining 22 cases, 12 and 10 cases showed mild and moderate staining respectively 
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(Table 1). The expression of Oct-4 was significantly correlated with stage (x
2
 = 5.725; 
P<0.01*). Particularly, the Oct-4 expression was higher in stage III-IV when compared 
with stage I-II. Additionally, Oct-4 staining was significantly higher in lymph node 
metastasis positive cases than that in lymph node metastasis negative cases (x
2
 = 6.907; 
P<0.009**). Oct-4 expression also showed a significant difference between well, 
moderate and poorly differentiated tumors (x
2
 = 15.265; P<0.001**). There was no 
significant difference between age, gender, location of tumor and Oct-4 expression 
(Table 2). The CAL27 cells showed increased expression of Oct-4 (Figure 2A (b)).  
Nanog 
The expression of Nanog which was primarily localized in the nucleus also showed 
cytoplasmic staining in some carcinoma cells (Figure 1B (d)). However, similar to Oct-4, 
nuclear expression of Nanog was considered as ‘positive staining’. Out of 60 cases of 
oral carcinoma, 17 and 14 cases showed negative and mild staining for Nanog 
respectively. The expression of Nanog was moderate in 10 cases and intense in 19 cases 
of oral squamous cell carcinoma (Table 1). The expression of Nanog was significantly 
higher in stage III-IV when compared with stage I-II (x
2
 = 6.877; P<0.009**). 
Statistically significant association was not found between age, gender, location of tumor 
and Nanog expression. Nanog expression was significantly correlated with lymph node 
metastasis (x
2
 = 8.210; p<0.004**). Moreover, expression of Nanog was associated with 
histological grade of oral carcinoma (x
2
 = 18.204; P<0.001**) (Table 2). Furthermore, 
intense expression of Nanog was observed in CAL27 cells (Figure 2A (c)).  
Association of β-catenin expression with Oct-4, Nanog and Involucrin in oral 
squamous cell carcinoma 
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The increased expression of β-catenin was found to be associated with the expression of 
Oct-4 in oral squamous cell carcinoma (Figure 1A (a) and (b)). In addition, Spearman’s 
correlation analysis revealed a significant positive association between the expression 
pattern of β-catenin and Oct-4 (P<0.001**, rs = 0.80) in oral carcinoma. Interestingly, 
cases with high β-catenin expression showed increased expression of Nanog. In addition, 
statistically significant positive correlation was found between the expression of β-
catenin and Nanog (P<0.001**, rs = 0.71) in oral squamous cell carcinoma (Figure 1B (c) 
and (d); Table 3).  
Oct-4 expression was significantly higher in cases showing intracellular expression of β-
catenin. Also, a positive linear relationship was found between localization of β-catenin 
and Oct-4 expression (P<0.001**, rs = 0.71). Moreover, Nanog expression was also 
higher in cases showing intracellular expression of β-catenin with a significant positive 
correlation (P<0.001**, rs = 0.67) obtained using Spearman’s correlation analysis (Table 
4).  Furthermore, Involucrin expression was not found in carcinoma tissues showing 
intracellular expression of β-catenin (Figure 1C (e) and (f)). 
 Co-localization of β-catenin with Oct-4, Nanog and Involucrin in oral squamous cell 
carcinoma.  
Double-immunofluorescence analysis was done in oral carcinoma tissues and H314 cell 
line. The expression of Oct-4 was predominantly found in oral carcinoma and H314 cells 
showing intracellular expression of β-catenin supporting the results of the correlation 
analysis (Figure 2A). In addition, the expression of Nanog was higher in oral carcinoma 
and H314 cells in which intracellular localization of β-catenin was observed (Figure 2A). 
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However, negative expression of Involucrin was observed in H314 cells showing 
intracellular expression of β-catenin (Figure 2B). 
 
Immunoblot and Co-immunoprecipitation analysis  
Western blot analysis was done to confirm the results obtained in Immunohistochemical 
and Immunofluorescence analyses. Western blot analysis revealed increased band 
intensity for β-catenin in carcinoma samples when compared with normal samples 
(Figure 2C (a)). The expression of both Oct-4 and Nanog were detected only in 
carcinoma samples and not in normal samples (Figure 2C (b) and (c)). On the other hand, 
the interaction between β-catenin and Oct-4 was studied using co-immunoprecipitation 
analysis (Figure 2C (d)). The interaction between β-catenin and Oct-4 was not observed 
in normal cases. Whereas, out of 10 carcinoma cases, 8 cases showed interaction between 
β-catenin and Oct-4 (Supplement table 1).  
Survival analysis 
The survival curves constructed using the Kaplan-Meier method and compared by log-
rank test showed that the β-catenin, Oct-4 and Nanog positive patients had poorer 
survival rates than those patients with negative expression in overall and disease-free 
survival (Figure 3 and 4). Additionally, the survival of patients with intracellular 
expression of β-catenin was worse when compared with other patients in overall and 
disease-free survival (Figure 3d and 4d).   Interestingly, β-catenin and Oct-4 double 
positive cases had a significant shorter survival time than other cases (Figure 3e and 4e). 
Moreover, β-catenin and Nanog double positive cases were significantly correlated with 
worse outcome in overall and disease-free survival (Figure 3f and 4f). Extent of lymph 
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node metastasis, clinical stage and poor differentiation status were significantly 
correlated with worst survival (Table 5; Supplement figure 1).  
The Univariate Cox Proportional Hazards Regression model revealed that high clinical 
stage, lymph node metastasis, high β-catenin expression, high Oct-4 expression and high 
Nanog expression had prognostic significance in overall and disease-free survival of 
patients with oral squamous cell carcinoma (Table 6). In addition, the Multivariate Cox 
Proportional Hazards Regression model indicate that clinical stage, β-catenin, Oct-4 and 
Nanog were independent prognostic factors in overall and disease-free survival of oral 
carcinoma patients (Table 7).   
 
Discussion 
 
Evidences to substantiate the cancer stem cell hypothesis have been emerging rapidly in 
various tumors. Several studies highlight the significant role of pluripotent markers and 
stem cell pathways in carcinogenesis. However, the molecular basis for the maintenance 
of cancer stem cell properties has not been extensively studied in oral squamous cell 
carcinoma.  In this study, we have investigated the expression pattern and correlation 
between Oct-4, Nanog and β-catenin in oral squamous cell carcinoma and CAL27 cell 
line. We also analyzed the association between the expression of these proteins with 
clinicopathological factors and prognosis in oral cancer.  On the other hand, we have 
studied the co-localization of β-catenin with Oct-4 and β-catenin with Nanog in oral 
squamous cell carcinoma tissues and H314 cell line. 
β-catenin signaling was found to play a significant role in oral squamous cell carcinoma. 
The absence of membranous and subsequent intracellular expression of β-catenin was 
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found to be a key event in oral cancer [9]. In the present study, absence of membranous 
and intense intracellular expression of β-catenin was mainly observed in oral carcinoma 
and CAL27 cells which were concurrent with earlier reports by Ishida et al [9] and 
Kobayashi et al [33]. This suggests that the β-catenin pathway might be re-activated and 
involved in oral carcinogenesis. Consistent with our previous findings [5], the expression 
of β-catenin was significantly correlated with lymph node metastasis, stage and grade of 
oral squamous cell carcinoma. This indicates that the expression of β-catenin may be 
related to the invasion and differentiation status in oral carcinoma cells. In addition, the 
expression of β-catenin seemed independent of age, gender and location of the tumor 
since the statistical significance was not reached. 
Oct-4, which plays a crucial role in maintaining the pluripotent state of embryonic stem 
cells, is not expressed in normal mature cells [34, 14].  Identification of Oct-4 in tumour 
tissues and cell lines is indicative of the reactivation of stem cell related pathways in 
cancer [14].  Recently, Oct-4 expression was also found in oral cancer stem-like cells [3].  
Consistent with the findings of Ge et al [35] and Chiou et al [3], nuclear expression of 
Oct-4 was mainly observed in oral carcinoma and CAL27 cells. However, cytoplasmic 
expression of Oct-4 was also observed in some carcinoma cells, similar to the expression 
pattern observed in rectal adenocarcinoma [36] and seminomas [37]. These results 
suggest the need for investigating the localization of Oct-4 in oral cancer. As mentioned 
by Ge et al [35], the expression of Oct-4 was significantly correlated with lymph node 
metastasis. This suggests that Oct-4 may be related to invasion and progression in oral 
cancer. Moreover, in line with the findings of Chiou et al [3], significant association was 
found between Oct-4 expression and the stage and grade of oral carcinoma. This indicates 
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that the expression of Oct-4 may be related to the differentiation status of oral carcinoma 
cells.  
Similar to Oct-4, Nanog is a pluripotent marker essential to maintain the self renewal of 
embryonic stem cells. Recently, the expression of Nanog was found in several tumors 
including oral squamous cell carcinoma [18-20, 3]. Interestingly, together with Oct-4, 
Nanog was found to induce cancer stem cell properties in lung adenocarcinoma [17]. In 
the present study, expression of Nanog was predominantly restricted to the nucleus in 
oral carcinoma and CAL27 cells. However, cytoplasmic staining was also found in some 
oral carcinoma cells as in cervical cancer [20]. These results suggest the need for 
investigating the specific function of Nanog based on its localization in oral cancer cells. 
Consistent with the findings of Chiou et al [3], the current study revealed that the 
expression of Nanog was higher in poorly differentiated tumours and in higher stages of 
oral carcinoma. This indicates that the expression of Nanog may be related to 
aggressiveness and differentiation of oral carcinoma cells. In addition, the expression of 
Nanog was significantly correlated with lymph node metastasis which was in agreement 
with the findings of Meng et al [38]. This suggests that the expression of Nanog may be 
related to the metastatic potential of oral carcinoma cells.  
β-catenin was found to maintain the self renewal potential of embryonic stem cells along 
with Oct-4 and Nanog [7].  In this study, we have found a significant association between 
Oct-4, Nanog and β-catenin in oral carcinoma. In addition, the intracellular expression of 
β-catenin was positively correlated with Oct-4 and Nanog expression in oral cancer. Co-
expression of β-catenin with Oct-4 and β-catenin with Nanog was also observed in oral 
carcinoma tissues and H314 cells. These results suggest a significant relationship among 
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β-catenin, Oct-4 and Nanog in maintaining proliferation and self renewal of oral 
carcinoma cells. Consistent with studies by Kamino et al [39] and Chou et al [26], we 
have found a decreased expression of Involucrin in oral squamous cell carcinoma tissues.  
Particularly, negative expression of Involucrin was observed in oral carcinoma cells 
which showed intracellular expression of β-catenin. This suggests that β-catenin signaling 
may help in maintaining proliferation of oral carcinoma cells by downregulating 
differentiation. As in embryonic stem cells [6, 7], the possible interaction between β-
catenin and Oct-4 was observed in oral squamous cell carcinoma tissues. This result 
explores the coordinated function of β-catenin and Oct-4 in oral carcinoma cells. 
However, further studies will help to determine the accurate role of their correlated 
expression which can further be applied for therapeutic target selection.  
In this study, the expression of β-catenin (particularly intracellular), Oct-4 and Nanog 
showed significant correlation with poor survival in oral squamous cell carcinoma as 
mentioned by Odajima et al [40] for β-catenin and Chiou et al [3] for Oct-4 and Nanog. 
This suggests that the reactivation and dysregulated expression of these proteins may be 
related to progression and aggressiveness in oral squamous cell carcinoma. Interestingly, 
β-catenin/Oct-4 and β-catenin/Nanog double positive cases showed worst survival in oral 
cancer. This indicates that the co-expression of β-catenin with Oct-4 and β-catenin with 
Nanog might be a valuable indicator of high risk cases. Moreover, the intracellular 
expression of β-catenin significantly correlates with poor survival in oral carcinoma 
which explores that the activated β-catenin signaling may contribute to cancer related 
mortality in oral carcinoma patients.  By univariate and multivariate analysis, we have 
found that β-catenin, Oct-4 and Nanog have prognostic value in oral squamous cell 
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carcinoma. Also, the present study showed that β-catenin, Oct-4 and Nanog might be 
used as independent prognostic markers of oral cancer which is concurrent with the 
findings of Odajima et al [40] for β-catenin and Chiou et al [3] for Oct-4 and Nanog. 
In conclusion, the expression pattern of β-catenin, Oct-4 and Nanog in oral carcinoma 
and CAL27 cells reveal the involvement of these proteins in oral carcinogenesis.  The 
positive correlation and co-expression of β-catenin with Oct-4 and β-catenin with Nanog 
suggests their coordinated role in oral squamous cell carcinoma. Also, it indicates that the 
β-catenin signaling might act synergistically with Oct-4 and Nanog in regulating 
proliferation and differentiation of oral carcinoma cells. Interestingly, the interaction 
between β-catenin and Oct-4 in oral carcinoma cells might be a crucial event in oral 
carcinogenesis which requires further investigation. Additionally, the prognostic value of 
β-catenin, Oct-4 and Nanog in oral squamous cell carcinoma, particularly, the co-
expression of β-catenin with Oct-4 and β-catenin with Nanog may be used to identify 
high-risk cases. Further studies on larger sample size and on the tumor inducing potential 
of β-catenin, Oct-4 and Nanog positive oral carcinoma cells could provide valuable 
information on the role of these proteins in oral carcinogenesis, their value as prognostic 
markers and their therapeutic significance. 
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Figure legends 
 
Figure 1: Immunostaining of β-catenin, Oct-4 and Nanog in oral squamous cell 
carcinoma. A) Serial section of oral carcinoma tissue showing positive staining for β-
catenin (a) (Inset: carcinoma cells showing membranous expression of β-catenin) and 
Oct-4 (b). B) Serial section of oral carcinoma tissue showing positive staining for β-
catenin (c) (Inset: carcinoma cells showing nuclear expression of β-catenin) and Nanog 
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(d). C) Serial section of oral carcinoma tissue showing positive staining for β-catenin (e) 
and Negative staining for Involucrin (f). Bar = 50µm. 
Figure 2: Co-localization of β-catenin, Oct-4 and Nanog was analyzed in CAL27 cells 
and carcinoma tissues using Immunofluorescence analysis. (A) Immunodetection of β-
catenin (a), Oct-4 (b) and Nanog (c) in CAL27 cell line. Section of oral carcinoma tissue 
showing positive staining for Oct-4 (d), intracellular expression of β-catenin (e) and 
expression of Oct-4 in cells showing intracellular expression of β-catenin (f); Arrows 
indicate co-localization of β-catenin and Oct-4 in oral carcinoma cell. Section of oral 
carcinoma tissue showing positive staining for Nanog (g), intracellular expression of β-
catenin (h) and expression of Nanog in cells showing intracellular expression of β-catenin 
(i); Arrows indicate co-localization of β-catenin and Nanog in oral carcinoma cell.  
H314 cells showing positive staining for Oct-4 (j), β-catenin (k) and expression of Oct-4 
in β-catenin positive H314 cells (l); Arrows indicate co-localization of β-catenin and Oct-
4 in H314 cell.  
H314 cells showing positive staining for Nanog (m), β-catenin (n) and expression of 
Nanog in β-catenin positive H314 cells (o); Arrows indicate co-localization of β-catenin 
and Nanog in H314 cell. Bar = 50µm. 
(B) H314 cells showing positive staining for β-catenin (a) and negative staining for 
Involucrin (b). Bar = 50µm. 
 
 
(C)       a.  Western blot for β-catenin (~ 92 kDa). Input controls for β-catenin in 
normal (Lane 1) and carcinoma (Lane 2) tissues; IgG controls for β-catenin in normal 
(Lane 3) and carcinoma (Lane 4) tissues.  
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      b.  Western blot for Oct-4 (~ 45 kDa). Input controls for Oct-4 in normal 
(Lane 1) and carcinoma (Lane 2) tissues; IgG controls for Oct-4 in normal (Lane 3) and 
carcinoma (Lane 4) tissues.  
 
 
      c.  Western blot for Nanog (~ 40 kDa). Input controls for Nanog in normal 
(Lane 1) and carcinoma (Lane 2) tissues; IgG controls for Nanog in normal (Lane 3) and 
carcinoma (Lane 4) tissues.  
            d.  Protein lysates were immunoprecipitated with anti- β-catenin and    
immunoblotted with anti-Oct-4.  
 
      e.  Western blot for β-actin (control).   
 
Figure 3:  Overall survival of patients with oral squamous cell carcinoma according to 
the expression of β-catenin (p = 0.0036) (a), Oct-4 ( p = 0.0001) (b), Nanog (p = 0.0001) 
(c), β-catenin localization ( p = 0.0001) (d), β-catenin + Oct-4 (double positive; p = 
0.0001) (e) and β-catenin + Nanog (double positive; p = 0.0001) (f) calculated by 
Kaplan-Meier method. Negative – includes categories 0 and 1
+
; Positive – includes 
categories 2
+
 and 3
+
; Intra. – intracellular; B+ / O+ - β-catenin and Oct-4 double positive; 
B+ / N+ - β-catenin and Nanog double positive. 
Figure 4:  Disease-free survival of patients with oral squamous cell carcinoma according 
to the expression of β-catenin ( p = 0.0395) (a), Oct-4 ( p = 0.0001) (b), Nanog ( p = 
0.0012) (c), β-catenin localization ( p = 0.0001) (d), β-catenin + Oct-4 (double positive; p 
= 0.0001) (e) and β-catenin + Nanog (double positive; p = 0.0001) (f) calculated by 
Kaplan-Meier method. Negative – includes categories 0 and 1
+
; Positive – includes 
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categories 2
+
 and 3
+
; Intra. – intracellular; B+ / O+ - β-catenin and Oct-4 double positive; 
B+ / N+ - β-catenin and Nanog double positive. 
Supplement Figure 1: Overall survival of patients with oral squamous cell carcinoma 
according to Stage (a), Lymph Node Metastasis (c) and Histological grade (e); Disease-
free survival of patients with oral squamous cell carcinoma according to Stage (b), 
Lymph Node Metastasis (d) and Histological grade (f) calculated by Kaplan-Meier 
method. Negative – includes categories 0 and 1
+
; Positive – includes categories 2
+
 and 3
+
; 
Mod. + Poor – moderate and poorly differentiated tumors; Well – well differentiated 
tumours. 
Supplement Figure 2: The co-localization between β-catenin and Oct-4/Nanog was 
analyzed in H314 cells. A. Expression of Oct-4 (a), β-catenin (b) , β-catenin + Oct-4 (c), 
DAPI (d), β-catenin + Oct-4 + DAPI (e) and β-catenin + DAPI (f) in H314 cell. B. 
Expression of Nanog (a), β-catenin (b) , β-catenin + Nanog (c), DAPI (d), β-catenin + 
Nanog + DAPI (e) and β-catenin + DAPI (f) in H314 cell. Yellow indicates Co-
localization of β-catenin (red) with Oct-4 / Nanog (green). C. Intracellular localization of 
β-catenin (a) and β-catenin + DAPI (b) in Oral carcinoma tissue. 
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Table: 1 
Immunodetection of β-catenin, Oct-4 and Nanog in oral squamous cell carcinoma. 
 
 
   Protein            No. of Cases                   0              1+               2+                 3+ 
 
 
   β-catenin    60                         10              9                11                 30 
 
   Oct-4                      60                         20             12                10                18 
 
   Nanog                        60                         17             14               10                 19 
 
      
 
0 (negative), no staining or <5% positive cells; 1
+ 
(mild)
 
, 5-15% positive cells; 2
+ 
(moderate), 16-25% positive cells and 3
+ 
(intense), >25% positive cells. 
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Table 2.  Correlation of β-Catenin, Oct and Nanog expression with clinicopathological factors 
                                 β-Catenin                         Oct-4                                                    Nanog  
     _____________________     x2 /     _______________________     x2 /     ________________________     x
2
 /          
      Negative(19)  Positive(41)  p-value     Negative(32)  Positive(28)   p-value    Negative(31)  Positive(29)     p-value     
                   No. of patients 
Age 
<60             32                      11                   21           0.232 /          17                    15             0.001 /            16                16                0.076 / 
                       p<0.63            p<0.97                                                 p<0.78 
>60                    28                       8                    20                                 15                    13                                    15                13 
Gender 
Male                  34                      12                   22           0.477 /           18                    16             0.005 /            17                17               0.087 / 
                                                                                          p<0.49                                                    p<0.94                                                 p<0.76 
Female               26                      7                     19                                 14                    12                                    14                 12  
Stage 
I-II                  27          13                    14           6.163 /          19                      8             5.725 /             19                  8              6.877 /              
           p<0.01*              p<0.01*                                     p<0.009** 
III-IV               33             6                     27                                 13                    20                                     12                21                                             
Lymph node 
Metastasis 
Negative             28          14                    14           8.155 /           20                      8             6.907 /             20                 8             8.210 /                                    
           p<0.004**              p<0.009**                                     p<0.004**            
Positive               32                      5                     27                                 12                    20                                     11                21                                             
Histological 
Grade   
                  
Well                    16                      9                      7                                  15                      1                                    15                  1                                    
Differentiated   
                                                                                            6.181 /                                                    15.265 /                                             18.204 /  
Moderately         20                      5                     15            p<0.04*        11                      9              p<0.001**     10                 10      p<0.001**                                                 
Differentiated  
Poorly                 24                      5                     19                                   6                     18                                     6                  18                                  
Differentiated 
Location of 
the tumours 
Tongue              20                      6                     14                                  12                     8                                     12                  8                                           
Buccal                  9                      3                       6                                   4                      5                                       4                  5             
                                                                                            0.275 /                                                    1.470 /                                               3.525 / 
Palate                   5                      2                       3            p<0.99            3                       2              p<0.83             2                  3           p<0.47                    
Gingiva               14                     4                     10                                   8                       6                                      9                  5                            
Floor of mouth    12                     4                      8                                    5                       7                                      4                  8 
_________________________________________________________________________________________________________________   
Negative (includes category 0 and 1
+
) and Positive (includes category 2
+
 and 3
+
). 
* Statistically significant, ** Statistically highly significant.  
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Table 3: Correlation between the expression pattern of β-Catenin, Oct-4 and Nanog in oral cancer. 
 
Expression of                                            Expression of Oct-4                                                    Expression of Nanog 
β-Catenin                               ____________________________________                ___________________________________             
                       
         (No. of patients = 60)         0 (20)       1
+
 (12)     2
+
 (10)    3
+
 (18)                           0 (17)       1
+
 (14)       2
+
 (10)       3
+ 
(19)       
 
     0             10                              9               1                 0             0                                  7               2                 1                0         
 
     1
+
            9                               6               2                 1             0                                   5              2                  2                0                           
                       
     2
+
         11                              5               3                 3             0                                  4              4                  3                 0 
                            
     3
+
           30                              0               6                 6            18
a
                                1              6                  4                19
b
                                           
 
0 (negative), no staining or <5% positive cells; 1
+ 
(mild)
 
, 5-15% positive cells; 2
+ 
(moderate), 16-25% positive cells and 3
+ 
(intense), 
>25% positive cells. 
 
a = Significant correlation was found between expression of β-Catenin and Oct-4 (p<0.001**, r = 0.80). 
b = Significant correlation was found between expression of β-Catenin and Nanog (p<0.001**, r = 0.71). 
** = Statistically highly significant. 
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Table 4: Correlation of β-Catenin localization with the expression patterns of Oct-4 and Nanog in oral squamous cell carcinoma. 
 
Localization of                                        Expression of Oct-4                                                        Expression of Nanog 
β-Catenin                               ____________________________________                ___________________________________             
                       
         (No. of patients = 60)                 0+1 (32)     2(10)     3(18)                        0+1 (31)       2(10)       3(19)              
 
     0             19                                       18                1               0                                                    16               3             0                         
 
     M           11                                         8                 3               0                                                     9               2             0                                           
                       
     I         30                                        6                 6              18
a 
                                                 6               5            19
b
                  
 
 
0+1(negative/mild; including categories 0 and 1
+
), 2 (moderate; including category 2
+
) and 3 (intense; including category 3
+
). 
 
0, negative; M, membranous and I, intra-cellular. 
 
a = Significant correlation was found between localization of β-Catenin and expression of Oct-4 (p<0.001**, r = 0.71). 
 
b = Significant correlation was found between localization of β-Catenin and expression of Nanog (p<0.001**, r = 0.67). 
 
** Statistically highly significant. 
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Table 5. Kaplan-Meier and log-rank analysis for Clinicopathological variables, β-catenin, 
Oct-4 and Nanog in relation to Overall and Disease-free survival of 60 patients with Oral 
Squamous Cell Carcinoma. 
________________________________________________________________________ 
                                              Overall Survival     Disease-free Survival 
      _______________________ ______________________ 
Variables         p value                          p value         
________________________________________________________________________ 
 
1. Stage (I, II /III, IV)         0.0003**         0.002** 
2. Grade (Well/Moderate,Poor)     0.018*         0.0009** 
3. LN Metastasis (+/-)         <0.001**                     0.041* 
4. β-catenin (+/-)                    0.003**         0.039* 
5. Oct-4 (+/-)                     <0.001**         <0.001** 
6. Nanog (+/-)                <0.001**          0.001** 
7. β-catenin+Oct-4         <0.001**          <0.001** 
        (B
+
/O
+ 
vs others) 
8. β-catenin+Nanog         <0.001**          <0.001** 
        (B
+
/N
+ 
vs others) 
9. β-catenin localization        <0.001**          <0.001** 
   (Intracellular vs others) 
________________________________________________________________________ 
-  = Includes category 0 and 1
+
, + = Includes category 2
+
 and 3
+
, LN = Lymph node, 
B
+
/O
+
 = β-catenin and Oct-4 double positive cases,  B
+
/N
+
 = β-catenin and Nanog double 
positive cases. 
* Statistically significant, ** Statistically highly significant.  
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Table 6. Univariate Cox proportional hazards regression analysis (Cox Method) for variables in relation to Overall and Disease-Free 
Survival of 60 patients with Oral Squamous Cell Carcinoma. 
___________________________________________________________________________________________________________ 
Overall Survival     Disease-free Survival 
    _______________________________________ _________________________________________ 
Variables    p value       Hazards Ratio   95% CI  p value        Hazards Ratio    95% CI 
___________________________________________________________________________________________________________ 
1. Stage (I, II /III, IV)   0.003** 8.966  2.069-38.857  0.001**  4.712  1.930-11.506 
2. Grade (Well/Moderate, Poor) 0.047*  0.130  0.017-0.976  0.005** 0.129  0.030-0.543 
3. LN Metastasis (+/-)                         0.003** 2.074  0.276-15.569  0.048*             2.085  1.007-4.317 
4. β-catenin (+/-)   0.021*  1.076  0.143-8.078  0.048*  2.349  1.008-5.477 
5. Oct-4 (+/-)    <0.001**        15.015  3.440-65.530  <0.001** 7.764  3.256-18.516 
6. Nanog (+/-)               0.001** 7.716  2.243-26.544  0.002** 3.222  1.514-6.860 
___________________________________________________________________________________________________________ 
-  = Includes category 0 and 1
+
, + = Includes category 2
+
 and 3
+
, LN = Lymph node. 
 
* Statistically significant, ** Statistically highly significant. 
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 Table 7. Multivariate Cox proportional hazards regression analysis (Cox Method) for variables in relation to Overall and Disease-Free 
Survival of 60 patients with Oral Squamous Cell Carcinoma. 
___________________________________________________________________________________________________________ 
Overall Survival     Disease-free Survival 
    _______________________________________ _________________________________________ 
Variables    p value       Hazards Ratio 95% CI  p value        Hazards Ratio 95% CI 
___________________________________________________________________________________________________________ 
 
1. Stage (I, II /III, IV)   0.015*    7.781  1.491-40.617  0.024*    3.254  1.165-9.091 
2. β-catenin     0.018*  1.403  0.561-12.621  0.008** 4.268  1.458-12.490 
3. Oct-4     0.022*  7.236  1.334-39.243  0.001** 9.288  2.982-28.930 
4. Nanog     0.025*  5.431  1.235-23.892  0.005** 4.591  1.578-13.356 
___________________________________________________________________________________________________________ 
* Statistically significant, ** Statistically highly significant 
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Supplement table 1 
 
Comparison of β-catenin – Oct-4 interaction between Normal and Carcinoma. 
________________________________________________________________________ 
 
    Group                                            β-catenin – Oct-4   
                                        ________________________________    
                             n                    Negative               Positive                                                 
________________________________________________________________________ 
 
1. Normal             6                        6                           0       
 
2. Carcinoma      10                        2                           8
a
                                  
_______________________________________________________________________ 
 
 
a = Significant difference was found between Normal and Carcinoma cases (p< 0.002**). 
 
** = Statistically highly significant. 
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